Regeneron Pharmaceuticals (STU:RGO) Inventories, Raw Materials & Components: €546 Mil (As of Mar. 2026)


STU:RGO Regeneron Pharmaceuticals Inc STU:RGO
83 GF Score
Price €569.20
GF Value €784.23
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Inventories, Raw Materials & Components?

Regeneron Pharmaceuticals STU:RGO -0.44% 83 Inventories, Raw Materials & Components is €546 Mil as of Mar. 2026. GuruFocus rates STU:RGO with a GF Score™ of 83/100 and a GF Value™ of €784.23 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Regeneron Pharmaceuticals's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €546 Mil.

Regeneron Pharmaceuticals's quarterly raw materials declined from Sep. 2025 (€605 Mil) to Dec. 2025 (€548 Mil) and declined from Dec. 2025 (€548 Mil) to Mar. 2026 (€546 Mil).

Regeneron Pharmaceuticals's annual raw materials increased from Dec. 2023 (€724 Mil) to Dec. 2024 (€840 Mil) but then declined from Dec. 2024 (€840 Mil) to Dec. 2025 (€548 Mil).

Regeneron Pharmaceuticals Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Inventories, Raw Materials & Components Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 638.88 772.57 723.79 839.92 547.84

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 775.61 652.24 604.92 547.84 545.56
STU:RGO
83GF Score
Regeneron Pharmaceuticals Inc STU:RGO
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €546 Mil mean?
Regeneron Pharmaceuticals (STU:RGO) has a Inventories, Raw Materials & Components of €546 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Inventories, Raw Materials & Components too high?
Regeneron Pharmaceuticals' current Inventories, Raw Materials & Components is €546 Mil. Overall, Regeneron Pharmaceuticals has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Inventories, Raw Materials & Components compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Inventories, Raw Materials & Components of €546 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Inventories, Raw Materials & Components is €546 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (STU:RGO) is currently considered Modestly Undervalued. The stock's GF Value™ is €784.23, compared to a current price of €569.20 — trading 27.4% below its estimated fair value. The current Inventories, Raw Materials & Components is €546 Mil. Regeneron Pharmaceuticals' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Regeneron Pharmaceuticals (STU:RGO), the current Inventories, Raw Materials & Components is €546 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (STU:RGO) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €569.20 is trading 27.4% below its estimated GF Value™ of €784.23. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:RGO:

  • Inventories, Raw Materials & Components: €546 Mil
  • GF Value™: €784.23 vs. price of €569.20 (27.4% below fair value)
  • GF Score™: 83/100 with 3 warning signs

No single metric tells the full story. See the STU:RGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
83GF Score

Get the complete analysis for STU:RGO

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€569.20
Price
€784.23
GF Value